Our Partners
Our 2025 Partners
If you'd like to become a partner for 5th Liquid Biopsy for Precision Oncology East Coast, get in touch here to partner and learn more about our bespoke sponsorship opportunities.
Program Partners
Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care.
Natera is a pioneer in molecular disease monitoring, offering a market-leading portfolio of ultra-sensitive assays and real-word data to support clinical development.
Natera’s flagship assay, Signatera™, is a tumor-informed circulating tumor DNA (ctDNA) assay developed for molecular residual disease (MRD) detection, recurrence monitoring, and treatment response monitoring. Signatera™ is supported by 100+ publications across 30+ tumor types and is covered by Medicare for eligible patients with CRC, breast cancer, NSCLC, MIBC, ovarian cancer, and patients receiving IO.
Leveraging its robust commercial footprint, Natera is transforming patient care—40% of U.S. oncologists are ordering, 300K+patients have been tested, and 1.2M+ Signatera™ tests have been ordered to date. Natera brings together technological innovation, a deep commitment to evidence building, and a proven ability to operationalize and commercialize at scale.
Personalis, Inc. is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. Our patented ACE (Accuracy and Content Enhanced) Technology forms the foundation of all Personalis products. ACE Technology improves every individual step in the next-generation sequencing (NGS) process, from nucleic acid extraction to sequencing assays, to data analytics. This makes it possible for us to achieve augmented coverage of difficult-to-sequence genomic regions that are missed with the use of conventional sequencing techniques. Using this comprehensive approach, we provide genomic data of the highest quality and accuracy to help biopharma drive their immuno-oncology clinical and biomarker discovery programs, thus enabling the rational design and development of effective cancer immunotherapies.
SAGA Diagnostics is a personalised cancer medicine and disease monitoring company focused on molecular genetic analyses of circulating tumor DNA and tissue biopsies.
Panel Partners
Guardant Health is a pioneer in non-invasive cancer diagnostics, addressing challenges across the cancer care continuum. The company has raised more than $200 million from leading venture capital firms and in 2014 launched Guardant360, the first comprehensive liquid biopsy for clinical use. Guardant Health is improving therapy selection for advanced cancer patients across the globe using its proprietary cell-free circulating tumor DNA NGS platform. Guardant Health is partnered with biopharmaceutical companies to prospectively screen patients for trial enrollment, develop companion diagnostics to support clinical adoption, and use retrospective analysis for early insights into patient response and tumor evolution, as well as accelerate the development of new therapies.
BioIVT enables smarter science and accelerates medical breakthroughs by delivering high-quality personalized biospecimen solutions and research services to life science and diagnostic industries. Recognized as an industry leader, BioIVT specializes in control and disease state samples including human and animal tissues or preparations, ADME-Tox products and research services, cell and gene therapy products, blood, and other biofluids.
Foresight Diagnostics is a privately held cancer diagnostics company and CLIA-registered laboratory. Its liquid biopsy platform, Foresight CLARITY™, is a novel assay that measures minimal residual disease (MRD) with a significantly higher level of sensitivity than most other
liquid biopsy tests, delivering a detection limit below 0.0001%, or one part-per-million. The improved sensitivity of Foresight CLARITY can provide actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with solid tumor and hematologic malignancies.
For more information, please visit:
www.foresight-dx.com
